Browse the search results

Peptide immunotherapy in mice depends upon sustained expression of co-inhibitory protein PD-1 in T cells.

Tumor stiffness blocks T cell migration in tumors.

Building on previous work (Lasagna-Reeves et al., 2015) it is shown that polyglutamine ATXN1 oligomers propagate locally in SCA1 mice, and that passive immunotherapy targeting soluble oligomers can lead to an improvement in motor coordination and a modest increase in life span.

The immune microenvironment has a pivotal role in hepatocellular carcinoma (HCC) progression and immune therapy resistance, and targeting this complex milieu holds great promise for improving therapeutic outcomes and patient prognoses in HCC management.

Tumors escape killing by the immune system through generating transient spatial cell-in-cell structures that are impenetrable to cytotoxic compounds including lytic granules and chemotherapy.

A mechanistic mathematical model informed by standard‐of‐care imaging and pathology predicts tumor responses to immunotherapy a priori on a per-patient basis.

Cluster analysis reveals convergent T cell clones reacting to tumor antigens, enabling intelligent optimization of cancer immunotherapy.

Cancer cell antigen presentation, a requirement for immune-mediated tumor rejection, is induced by dihydroorotate dehydrogenase-inhibitor-mediated cancer cell pyrimidine nucleotide depletion via P-TEFb-dependent transcriptional upregulation of MHC-I and related genes.

Stereotactic body radiotherapy combined with immunotherapy and chemotherapy in neoadjuvant setting exhibited a promising anti-tumor activity and an acceptable safety profile in triple-negative breast cancer patients.

Tissue-resident natural killer cells are important mediators of CD8 T responses in human cancers and these cells can be harnessed to increase immunity against pancreatic ductal adenocarcinoma.